NCT02440828View on ClinicalTrials.gov

Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 1, 2020

Study Completion Date

July 1, 2020

Conditions
Ventilator Associated Pneumonia (VAP)
Interventions
DRUG

tobramycin inhalation

tobramycin inhalation 300 mg twice daily

DRUG

placebo

NaCl 0.9% inhalation 4 ml twice daily

Trial Locations (2)

3000CA

Erasmus MC, Rotterdam

08036

Hospital Clinic, Barcelona

Sponsors
All Listed Sponsors
collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Erasmus Medical Center

OTHER